A study of plasminogen in patients with amyotrophic lateral sclerosis and Parkinson’s disease

Talengen Institute of Life Sciences0 个研究点目标入组 40 人开始时间: 2023年1月27日最近更新: 2023年11月28日

试验速览

暂无简介。

•1. Male and female patients =18 years of age with sporadic or familial ALS or PD
•2. If taking riluzole and/or edaravone, must be on a stable dose prior to screening

•1. History of a clinically significant non-ALS or PD neurologic disorder
•2. Inability to swallow capsules.
•3. Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus
•4. Women who are pregnant, planning to become pregnant, or are breastfeeding.
•5. Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or any form of oxygen supplementation.
•6. Current or anticipated need for a diaphragm pacing system (DPS).
•7. Currently using glucocorticoids or have a history of regular systemic glucocorticoid use within the last 12 months.
•8. Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.

发起方

Talengen Institute of Life Sciences